Professor Michael Berk is currently an NHMRC Senior Principal Research Fellow and Alfred Deakin Chair of Psychiatry at Deakin University and Barwon Health, where he heads the IMPACT Strategic Research Centre. He holds an Honorary position at both Melbourne and Monash University and is a highly cited researcher with over 800 published papers predominantly in mood disorders. His major interests are in the discovery and implementation of novel therapies, and risk factors and prevention of psychiatric disorders.

Prof Michael Berk discusses the evidence of NAC in addiction, Autism, OCD, and in Mild Traumatic Brain Injury.

Take-home Points

• N-Acetylcysteine (NAC) can cross the blood-brain barrier.

• Studies of NAC in autism have revealed negative results on the total aberrant behavior checklist.

• Administration of NAC (within 24 hours) might be a possible future treatment for a variety of forms of trauma.

Full article: https://psychscenehub.com/video/appli...